Publications
Detailed Information
The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, H. S. | - |
dc.contributor.author | Kim, J. W. | - |
dc.contributor.author | Cho, J. Y. | - |
dc.contributor.author | Chung, H. H. | - |
dc.contributor.author | Song, Y. S. | - |
dc.contributor.author | Kang, S. B. | - |
dc.contributor.author | Kim, S. H. | - |
dc.contributor.author | Park, N. H. | - |
dc.date.accessioned | 2012-06-04T02:23:33Z | - |
dc.date.available | 2012-06-04T02:23:33Z | - |
dc.date.issued | 2009-08 | - |
dc.identifier.citation | EJSO; Vol.35 8; 870-876 | ko_KR |
dc.identifier.issn | 0748-7983 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76758 | - |
dc.description.abstract | Background: We sought to identify the role of serum CA-125 levels in early-stage epithelial ovarian cancer (EOC) on preoperative CT and MRI. Methods: Clinical data of 101 patients with early-stage EOC on preoperative CT and MRI were collected between January 2000 and December 2007. Clinical stage I (n = 59) was defined as tumor limited to the ovaries with or without ascites, whereas clinical stage II (n = 42) was defined as tumor within the pelvis with or without ascites. The primary endpoint was to investigate the efficacy of serum CA-125 levels for the prediction of advanced-stage disease, and secondary endpoints were to evaluate the accuracy of preoperative CT and MRI, and to examine the role of serum CA-125 levels as a prognostic factor for survival. Results: The results of preoperative CT and MRI were concordant with no peritoneal implants outside the pelvis in 50/101 (50%) and no lymph node metastasis in 71/101 (70%) patients. The receiver operating characteristic curves showed that best cut-off values of serum CA-125 levels were 320 U/ml (71% sensitivity, 84% specificity) and 5 10 U/ml (67% sensitivity, 80% specificity) for the prediction of peritoneal implants outside the pelvis and lymph node metastasis. The serum CA-125 level (>= 320 U/ml) was a significant factor for the prediction of advanced-stage disease (adjusted OR, 7.43: 95% CI, 2.39-23.04). However, it was not an independent prognostic factor for survival. Conclusions: Serum CA-125 levels may be very useful for the prediction of advanced-stage disease in early-stage EOC on preoperative CT and MRI. (C) 2009 Elsevier Ltd. All rights reserved. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER SCI LTD | ko_KR |
dc.subject | Serum CA-125 level | ko_KR |
dc.subject | MRI | ko_KR |
dc.subject | CT | ko_KR |
dc.subject | Advanced-stage disease | ko_KR |
dc.subject | Early-stage epithelial ovarian cancer | ko_KR |
dc.title | The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1016/j.ejso.2009.01.005 | - |
dc.citation.journaltitle | EJSO | - |
dc.description.citedreference | Kim HS, 2008, ONKOLOGIE, V31, P315, DOI 10.1159/000131270 | - |
dc.description.citedreference | WAKABAYASHI MT, 2008, J NATL COMPR CANC NE, V6, P803 | - |
dc.description.citedreference | Kim HS, 2008, ACTA OBSTET GYN SCAN, V87, P1136, DOI 10.1080/00016340802478158 | - |
dc.description.citedreference | KIM HS, 2008, J GYNECOL ONCOL, V19, P75 | - |
dc.description.citedreference | Liu PY, 2007, J CLIN ONCOL, V25, P3615, DOI 10.1200/JCO.2006.09.4540 | - |
dc.description.citedreference | Castellucci P, 2007, NUCL MED COMMUN, V28, P589 | - |
dc.description.citedreference | Chan JK, 2007, BRIT J CANCER, V96, P1817, DOI 10.1038/sj.bjc.6603803 | - |
dc.description.citedreference | Cho YH, 2006, GYNECOL ONCOL, V103, P878, DOI 10.1016/j.ygyno.2006.05.022 | - |
dc.description.citedreference | Heintz APM, 2006, INT J GYNECOL OBSTET, V95, pS161 | - |
dc.description.citedreference | Jemal A, 2006, CA-CANCER J CLIN, V56, P106 | - |
dc.description.citedreference | Santillan A, 2005, J CLIN ONCOL, V23, P9338, DOI 10.1200/JCO.2005.02.2582 | - |
dc.description.citedreference | Crawford SC, 2005, J CLIN ONCOL, V23, P8802, DOI 10.1200/JCO.2005.02.1287 | - |
dc.description.citedreference | Panici PB, 2005, J NATL CANCER I, V97, P560, DOI 10.1093/jnci/dji102 | - |
dc.description.citedreference | Ricke J, 2003, EUR RADIOL, V13, P943, DOI 10.1007/s00330-002-1712-8 | - |
dc.description.citedreference | Wang ZH, 2003, CHINESE MED J-PEKING, V116, P588 | - |
dc.description.citedreference | Drieskens O, 2003, GYNECOL OBSTET INVES, V55, P130, DOI 10.1159/000071525 | - |
dc.description.citedreference | Camatte S, 2002, J AM COLL SURGEONS, V195, P332 | - |
dc.description.citedreference | Tsumura N, 1998, INT J CANCER, V79, P526 | - |
dc.description.citedreference | Onda T, 1998, CANCER, V83, P1555 | - |
dc.description.citedreference | LORENZEN M, 1998, AKTUELLE RADIOL, V8, P266 | - |
dc.description.citedreference | diRe F, 1996, GYNECOL ONCOL, V62, P360 | - |
dc.description.citedreference | Onda T, 1996, CANCER, V78, P803 | - |
dc.description.citedreference | LAFIANZA A, 1992, ROFO FORTSCHR RONTG, V157, P162 | - |
dc.description.citedreference | BUY JN, 1988, RADIOLOGY, V169, P691 | - |
dc.description.citedreference | TRILLER J, 1984, ROFO FORTSCHR RONTG, V141, P35 | - |
dc.description.citedreference | YOSHIMURA S, 1984, AM J OBSTET GYNECOL, V148, P716 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.